Physician profile
Amanda L Morris
NPI 1730479270
$12,939.32
in general payments reported to CMS, 2019-2025
52 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $1,167 · 2021: $2,006 · 2022: $3,369 · 2023: $2,511 · 2024: $1,239 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,206 · Gift: $59.40 · Education: $32.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.97 |
| Gift | $59.40 |
| Education | $32.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,818.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $1,562.06 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Horizon Therapeutics Plc | $1,324.75 | 2019-2023 | Tepezza |
| Lilly USA, LLC | $755.61 | 2019-2025 | Mounjaro, Jardiance, Taltz |
| Astrazeneca Pharmaceuticals LP | $530.51 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $498.39 | 2019-2024 | |
| Abbvie INC. | $481.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.66 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $444.40 | 2022-2025 | |
| Amgen INC. | $407.77 | 2019-2025 | Tepezza, Tavneos, Evenity |
| Dexcom, INC. | $381.87 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $353.29 | 2022-2024 | |
| Corcept Therapeutics | $304.21 | 2021-2025 | Korlym |
| Amarin Pharma, INC. | $304.09 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $282.53 | 2019-2020 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $273.38 | 2019-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $251.80 | 2020-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $226.09 | 2022-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $201.65 | 2019-2025 | Omnipod |
| Antares Pharma, INC. | $190.16 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $189.22 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $150.46 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Amryt Pharma Holdings LTD | $142.70 | 2022-2023 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $120.81 | 2022-2024 | Strensiq |
| Glaxosmithkline, LLC. | $105.36 | 2021-2025 | Benlysta, Arexvy, Shingrix |
| Ucb, INC. | $85.05 | 2022-2025 | Bimzelx |
| Janssen Biotech, INC. | $84.39 | 2022-2023 | Tremfya |
| Pfizer INC. | $83.02 | 2022-2023 | |
| Shire North American Group INC | $78.49 | 2019 | |
| Merck Sharp & Dohme LLC | $76.92 | 2019-2021 | |
| Rhythm Pharmaceuticals, INC. | $72.99 | 2023-2025 | Imcivree, Imcivree |
| Sobi, INC | $69.81 | 2023-2025 | |
| Madrigal Pharmaceuticals | $65.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Actelion Pharmaceuticals US, INC. | $56.48 | 2021-2025 | Opsumit, Uptravi |
| Ibsa Pharma INC. | $46.69 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $45.57 | 2023-2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $43.45 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $40.59 | 2022-2023 | Unithroid |
| Companion Medical, INC. | $39.93 | 2019-2020 | |
| Medtronic Minimed, INC. | $32.18 | 2019-2020 | |
| Genentech USA, INC. | $31.77 | 2025 | Gazyva |
| Sequel Med Tech, LLC | $25.47 | 2025 | Twiist |
| Argenx US, INC. | $25.40 | 2025 | Vyvgart |
| Alfasigma USA, INC. | $22.76 | 2020 | |
| Aurinia Pharma U.S., INC. | $21.78 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $16.24 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.10 | 2022 | |
| Tonix Medicines, INC. | $15.39 | 2025 | Tonmya |
| Eusa Pharma (US) LLC | $14.05 | 2022 | |
| Zealand Pharma US, INC. | $12.59 | 2021 | |
| Beta Bionics, INC. | $10.88 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.